Vericiguat

Sold as VERQUVO · given by oral

Five to ten years until it comes off patent
6.3 yr
Until anyone may copy it
Protection runs to 2032-11-26
23
Trials running now
50 registered in total
In routine use
Furthest stage reached
already in routine clinical use
3
Organisations running trials
lead sponsors on record
01

Who owns it, and until when

Merck Sharp And Dohme Llc
Approval holder
the only company permitted to sell it today
2032-11
Last patent expires
latest patent filed against this product
2029-01
FDA exclusivity ends
a separate protection granted at approval

Whichever date falls later is when other manufacturers may apply to sell copies. Price typically falls steeply within a year of that point, and with it any company's ability to recover the cost of new research on the molecule. That is when it becomes a candidate for the ledger on the first tab.

02

What it is being tested for

Heart FailureChronic Heart Failure With Reduced EjeChronic Heart Failure
03

Who is paying for the research

Bayer
Company
21
Merck Sharp & Dohme LLC
Company
3
Daejeon St. Mary's hospital
University or hospital
1

Who funds the trials matters after protection lapses. Company-funded work usually stops once exclusivity ends; university, hospital and government-funded work does not, and is the research most likely to continue on this molecule afterwards.

04

The trials themselves

NCT06320951Phase 22026 · 200 people · not yet recruiting
VITAL-IMPACT: Improving Cardiometabolic Heal

Expiry dates are what the patent holder has filed; litigation, paediatric extensions and settlements routinely move them, so read these as the earliest plausible date rather than a schedule. Not medical advice.

← Back to the patent line